Vaccine effectiveness of 52.8% seen for ED visits, 52.3% for noncritical hospitalization, 50.4% for critical hospitalization.

Children and adolescents with multiple sclerosis (MS) have a range of symptoms, signs, and diagnoses within 5 years before diagnosis, according to a study publi ...

Our work suggests that targeting the brain-muscle axis could offer new treatment strategies for muscle fatigue.

HealthDay News — The prevalence of post-COVID-19 condition (PCC) was 8.4% among US adults in 2023, according to a research letter published online in JAMA Network Open.

Our work suggests that targeting the brain-muscle axis could offer new treatment strategies for muscle fatigue.

CagriSema is a fixed-dose combination of cagrilintide, a long-acting amylin analogue, and semaglutide, a glucagon-like peptide-1 receptor agonist.

The Food and Drug Administration (FDA) has approved Alyftrek ™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one ...

Nursing staff interventions regarding shock team activation significantly improved the time of diagnosis and acceptance of patients with cardiogenic shock. A cardiovascular specialty hospital in ...

The Food and Drug Administration (FDA) has approved Ryoncil ® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft vs host disease (SR-aGvHD) in pediatric patients 2 months of age ...